Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 9, 2015

View Archived Issues

Foamix reports topline results from phase II study of FDX-104

bluebird bio and ViroMed collaborate to develop CAR T-cell therapies

Athlete receives Zilosul for bone marrow edema under TGA Special Access Scheme

Merck & Co. reveals strategy to develop biosimilars in Canadian market

New trial evaluates use of stem cells to treat Alzheimer's disease

Cynata and Regience sign letter of intent for Cymerus alliance in Japan

Amgen and Merck & Co. form cancer immunotherapy collaboration

Samumed reports preliminary efficacy data from phase II study of SM-04554 for androgenetic alopecia

Tagging AR for degradation shows promise for prostate cancer

ADC Therapeutics cleared to start phase I trial of ADCT-402

Preclinical results for anticancer ADC and antibodies

Evofosfamide fails to increase overall survival in phase III trials

Johnson & Johnson acquires Novira Therapeutics

Midatech Pharma acquires DARA BioSciences

Novel neprilysin inhibitors exhibit good renal profile

Abcodia's ROCA test available in select U.S. states

University of Pennsylvania patents rAAV expressing dual antibody constructs

Roche discloses HER3/HER2 bispecific antibodies

Immunotope presents DENV universal vaccine candidates

Theravance initiates first-in-human study of NEP inhibitor TD-0714

EMA accepts MAA for Sandoz's etanercept biosimilar

Baxalta's Vonvendi is first FDA-approved recombinant von Willebrand factor

First clinical results show feasibility of first-in-class HGF/VEGF inhibitor MP-0250 in oncology

FDA approves Kanuma as first therapy for patients with lysosomal acid lipase deficiency

IL-15N72D/IL-15Ralpha-Fc superagonist complex shows promise for high-risk hematologic malignancies

Luspatercept receives FDA fast track designation for anemia in lower-risk MDS

FDA grants breakthrough therapy designation to Kite's KTE-C19

Sunesis files MAA for vosaroxin for AML in older adults